PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
14 mai 2021 08h00 HE
|
PMV Pharmaceuticals, Inc.
Presented late breaking preclinical data on PC14586, the Company’s first-in-class, tumor-agnostic, investigational small molecule p53 Y220C reactivator at the American Association for Cancer Research...
PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference
05 mai 2021 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021
10 avr. 2021 13h31 HE
|
PMV Pharmaceuticals, Inc.
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activityRobust in vivo tumor regression observed with once daily oral dosingPharmacodynamic biomarkers of p53 activation developed...
PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum
06 avr. 2021 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
10 mars 2021 16h31 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
03 mars 2021 16h01 HE
|
PMV Pharmaceuticals, Inc.
Initiated Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationPC14586 granted Fast Track...
PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference
23 févr. 2021 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
16 févr. 2021 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
24 nov. 2020 17h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
23 nov. 2020 08h00 HE
|
PMV Pharmaceuticals, Inc.
PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing functionPhase 1/2 study is enrolling patients with advanced solid tumors that have a p53...